North America Bioproduction Market Forecast to 2030 - Regional Analysis - by Product, Application, Equipment, and End User

Description

List of Tables

The North America bioproduction market was valued at US$ 10,947.48 million in 2022 and is expected to reach US$ 31,373.65 million by 2030; it is estimated to register a CAGR of 14.1% from 2022 to 2030.

Rising Adoption of Regenerative Medicines Fuels North America Bioproduction Market

Regenerative therapies help in the regeneration of cells, tissues, and organs to restore their functions. A number of regenerative medicine applications for human clinical trials are submitted to the Food and Drug Administration (FDA) each year. As per the Alliance for Regenerative Medicine, in 2019 (Q3), 1,052 clinical trials utilizing regenerative medicine were underway globally; 218 cellular therapy trials were underway (41 Phase I, 147 Phase II, 30 Phase III) in 2019. Rapid advancements are being made in regenerative medicines to provide effective solutions for chronic conditions. Cell therapy is one of the fastest-growing segments of the regenerative medicine domain. Novartis' Kymriah was the first cell therapy solution offered to treat B-cell acute leukemia. Moreover, RepliCel, a regenerative medicine provider, has a wide range of regenerative medicine products in the pipeline, with three products-RCH-01, RCS-01, and RCT-01-in the development phase. Further, Sernova is engaged in the development of regenerative medicine technologies and has a huge pipeline of products for conditions such as diabetes, hemophilia A, and hyperthyroidism. Thus, the rising adoption of regenerative medicines is driving the bioproduction market.

North America Bioproduction Market Overview

The North America bioproduction market is subsegmented into the US, Canada, and Mexico. In Mexico, the demand for cell therapy is quite noteworthy owing to growing medical tourism for stem cell therapy. The bioproduction market in North America accounted for the largest market share in 2022 due to increasing incidence of diabetes and infertility, as well as rising product developments in biosimilars.

Growing incidences of genetic and cellular disorders are leading to increasing demand for cell therapies. A 2020 PhRMA report on the cell and gene therapy pipeline revealed that there are 400 cell and gene therapies in development to target a variety of diseases and conditions from cancer to genetic disorders to neurologic conditions in the US. As of February 2020, nine cell or gene therapy products were approved in the US to treat cancer, eye diseases and rare hereditary diseases. Also, an increasing number of start-ups are innovating cell therapies in the country.

North America Bioproduction Market Revenue and Forecast to 2030 (US$ Million)

North America Bioproduction Market Segmentation

The North America bioproduction market is categorized into product, application, equipment, end user, and country.

Based on product, the North America bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held the largest North America bioproduction market share in 2022.

In terms of application, the North America bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held the largest North America bioproduction market share in 2022.

By equipment, the North America bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held the largest North America bioproduction market share in 2022.

In terms of end user, the North America bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held the largest North America bioproduction market share in 2022.

By country, the North America bioproduction market is segmented into the US, Canada, and Mexico. The US dominated the North America bioproduction market share in 2022.

Bio-Rad Laboratories Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, Lonza Group AG, Merck KGaA, Sartorius AG, and Thermo Fisher Scientific Inc. are some of the leading companies operating in the North America bioproduction market.

Product Code: BMIRE00030058

Table of Content

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Bioproduction Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Rising Adoption of Regenerative Medicines
- 4.1.2 Increasing Prevalence of Chronic Diseases
4.2 Market Restraints
- 4.2.1 High Cost of Cell Therapy and Biosimilar Manufacturing
4.3 Market Opportunities
- 4.3.1 Patent Expiry of Blockbuster Biologics
4.4 Future Trends
- 4.4.1 Shift Toward Automated Cell Therapy Manufacturing
4.5 Impact Analysis

5. Bioproduction Market - North America Market Analysis

5.1 North America Bioproduction Market Revenue (US$ Mn), 2020 - 2030

6. North America Bioproduction Market - Revenue and Forecast to 2030 - by Product

6.1 Overview
6.2 North America Bioproduction Market Revenue Share, by Product 2022 & 2030 (%)
6.3 Biologics and Biosimilars
- 6.3.1 Overview
- 6.3.2 Biologics and Biosimilars: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Vaccines
- 6.4.1 Overview
- 6.4.2 Vaccines: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Cell and Gene Therapies
- 6.5.1 Overview
- 6.5.2 Cell and Gene Therapies: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Nucleic Acid Therapeutics
- 6.6.1 Overview
- 6.6.2 Nucleic Acid Therapeutics: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
6.7 Others
- 6.7.1 Overview
- 6.7.2 Others: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Bioproduction Market - Revenue and Forecast to 2030 - by Application

7.1 Overview
7.2 North America Bioproduction Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Cancer
- 7.3.1 Overview
- 7.3.2 Cancer: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Cardiovascular Diseases
- 7.4.1 Overview
- 7.4.2 Cardiovascular Diseases: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Rheumatoid Arthritis
- 7.5.1 Overview
- 7.5.2 Rheumatoid Arthritis: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Hematological Disorders
- 7.6.1 Overview
- 7.6.2 Hematological Disorders: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Diabetes
- 7.7.1 Overview
- 7.7.2 Diabetes: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
7.8 Others
- 7.8.1 Overview
- 7.8.2 Others: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Bioproduction Market - Revenue and Forecast to 2030 - by Equipment

8.1 Overview
8.2 North America Bioproduction Market Revenue Share, by Equipment 2022 & 2030 (%)
8.3 Consumables and Accessories
- 8.3.1 Overview
- 8.3.2 Consumables and Accessories: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Downstream Equipment
- 8.4.1 Overview
- 8.4.2 Downstream Equipment: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Bioreactors
- 8.5.1 Overview
- 8.5.2 Bioreactors: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.5.2.1 North America: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
8.6 Upstream Equipment
- 8.6.1 Overview
- 8.6.2 Upstream Equipment: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Bioproduction Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 North America Bioproduction Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Biopharmaceutical Companies
- 9.3.1 Overview
- 9.3.2 Biopharmaceutical Companies: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Contract Manufacturing Organizations
- 9.4.1 Overview
- 9.4.2 Contract Manufacturing Organizations: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Others
- 9.5.1 Overview
- 9.5.2 Others: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Bioproduction Market - Revenue and Forecast to 2030 - Country Analysis

10.1 North America: Bioproduction Market
- 10.1.1 US: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  - 10.1.1.1 Overview
  - 10.1.1.2 US: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  - 10.1.1.3 US: Bioproduction Market, by Product, 2020-2030 (US$ Million)
  - 10.1.1.4 US: Bioproduction Market, by Application, 2020-2030 (US$ Million)
  - 10.1.1.5 US: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
    - 10.1.1.5.1 US: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
  - 10.1.1.6 US: Bioproduction Market, by End User, 2020-2030 (US$ Million)
  - 10.1.1.2 Canada: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.2.1 Overview
    - 10.1.1.2.2 Canada: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.2.3 Canada: Bioproduction Market, by Product, 2020-2030 (US$ Million)
    - 10.1.1.2.4 Canada: Bioproduction Market, by Application, 2020-2030 (US$ Million)
    - 10.1.1.2.5 Canada: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
    - 10.1.1.2.5.1 Canada: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
    - 10.1.1.2.6 Canada: Bioproduction Market, by End User, 2020-2030 (US$ Million)
  - 10.1.1.3 Mexico: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.3.1 Overview
    - 10.1.1.3.2 Mexico: North America Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.3.3 Mexico: Bioproduction Market, by Product, 2020-2030 (US$ Million)
    - 10.1.1.3.4 Mexico: Bioproduction Market, by Application, 2020-2030 (US$ Million)
    - 10.1.1.3.5 Mexico: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
    - 10.1.1.3.5.1 Mexico: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
    - 10.1.1.3.6 Mexico: Bioproduction Market, by End User, 2020-2030 (US$ Million)

11. Bioproduction Market-Industry Landscape

11.1 Overview
11.2 Growth Strategies in the Bioproduction Market
11.3 Inorganic Growth Strategies
- 11.3.1 Overview
11.4 Organic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Lonza Group AG
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Danaher Corp
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Sartorius AG
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Thermo Fisher Scientific Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Merck KGaA
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 F. Hoffmann-La Roche Ltd
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Bio-Rad Laboratories Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms